Compare Neurocrine Biosciences Inc (NBIX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Royal Caribbean Cruises Ltd — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Royal Caribbean Cruises Ltd trades at $287.72 (market cap $76.75B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 4.4× Neurocrine Biosciences Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.75% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RCL | |
|---|---|---|
Market Cap | $17.40B | $76.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $365.84 |
52-Week Low | $123.10 | $246.71 |
Enterprise Value | $16.49B | $98.03B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royal Caribbean (RCL) trades at $287.90, near its 52-week high, with a modest 0.33% daily gain. The stock shows strong fundamental momentum, with revenue growing from $8.8B in 2022 to $17.9B in 2025 and net income surging to $4.3B. However, technical indicators signal a bearish trend, with moving averages and oscillators pointing to near-term pressure. Recent news highlights earnings anticipation and board appointments, while analyst consensus remains bullish with a $328 price target.
The outlook for RCL is positive based on robust earnings growth and expanding profit margins, but risks include high debt levels and potential economic sensitivity. Investor sentiment is mixed, with technical weakness offset by strong fundamentals. The stock presents a long-term opportunity if it can maintain operational execution amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
